Skip to content
TriangleGet started
← Full study record

NCT06039384 · MORE INFO

Limitations, agreements, and source contact

A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation · Source last updated 2026-09-08

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
other Details
Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated due to a strategic business decision. There were no safety concerns that contributed to this decision.
point Of Contact
email
medinfo@incyte.com
organization
Incyte Corporation
phone
1-855-463-3463
title
Study Director
Complete source fields
certain Agreement
other Details
Following the first publication, the Institution and/or Principal Investigator may publish data or results from the Study, provided, however, that the Institution and/or Principal Investigator submits the proposed publication to the Sponsor for review at least sixty (60) days prior to the date of the proposed publication. Sponsor may remove from the proposed publication any information that is considered confidential and/or proprietary other than Study data and results.
pi Sponsor Employee
false
restriction Type
OTHER
restrictive Agreement
true
limitations And Caveats
description
This study was terminated due to a strategic business decision. There were no safety concerns that contributed to this decision.
point Of Contact
email
medinfo@incyte.com
organization
Incyte Corporation
phone
1-855-463-3463
title
Study Director

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Independent clinical review pending · Not medical advice